http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Study for grain-filling of rice using 13C labeling flow-metabolome analysis
Okamura Masaki,Hirai Masami Yokota,Sawada Yuji,Okamoto Mami,Arai-Sanoh Yumiko,Yoshida Hiroe,Mukouyama Takehiro,Adachi Shunsuke,Fushimi Erina,Yabe Shiori,Nakagawa Hiroshi,Kobayashi Nobuya,Kondo Motohik 한국작물학회 2017 한국작물학회 학술발표대회 논문집 Vol.2017 No.-
Masayuki Sekine,Takayuki Enomoto,Masami Arai,Hiroki Den,Hiroyuki Nomura,Takeshi Ikeuchi,Seigo Nakamura 대한부인종양학회 2022 Journal of Gynecologic Oncology Vol.33 No.4
Objective: and mutation carriers are recommended to undergo risk-reducing salpingo-oophorectomy (RRSO) by age 40 and 45, respectively. However, the carriers have a different way of thinking about their life plan. We aimed to investigate the distribution of age at diagnosis of ovarian cancer (OC) patients to examine the optimal timing of RRSO in the carriers. Methods: We examined a correlation between age at diagnosis of OC and common mutation types in 3,517 probands that received genetic testing. Among them, germline mutation (g m), germline mutation (g m) and germline wild-type (g wt) were found in 185, 42 and 241 OC patients, respectively. Results: The average age at diagnosis of OC in g m and g m was 51.3 and 58.3 years, respectively, and the difference from g wt (53.8 years) was significant. Theg m carriers did not develop OC under the age of 40. The average age was 50.1 years for L63X and 52.8 years for Q934X in , and 55.1 years for R2318X and 61.1 years for STOP1861 in . The age at diagnosis in L63X or R2318X carriers was relatively younger than other or carriers, however their differences were not significant. With L63X and R2318X carriers, 89.4% (42/47) and 100% (7/7) of women were able to prevent the development of OC, respectively, when RRSO was performed at age 40. Conclusion: There appears to be no difference in the age at diagnosis of OC depending on the type of common mutation. Further analysis would be needed.
포메라니안의 성장호르몬 반응성탈모증에 대한 사람성장호르몬 및 mitotane(op'-DDD, Lysodren)에 의한 치료증례
志尾大一(Daiichi SHIO),? 雅之(Masayuki SEKI),久万美千代(Michiyo KUMAN),神?雅巳(Masami KOUNOSE),荒井延明(Nobuaki ARAI),藤川一人(Kazuhito FUJIKAWA),山形洋之(Kiroyuki YAMAGATA),棚田敦司(Atsushi TANADA),永井辰弘(Tatsuhiro NAGAI),中山洋治(Youj 로얄에이알씨 주식회사 2004 로얄동물임상의학 Vol.2 No.1
양측성(兩側性), 대측성탈모(對側性脫毛)와 색소과잉(色素過剩)을 나타낸 2두의 거세(去勢)한 수컷의 포메라니안이 내원하였다. ACTH부하시험(負荷試驗), 저용량(低用量) Dexamethasone억제시험 및 성장호르몬(GH) 응답성시험(Xylazine자극시험)에 의하여 GH반응성탈모증(反應性脫毛症)으로 진단하고 사람GH제제(製劑) 0.1 IU/㎏를 1주일간에 2회씩 근육 내에 투여하고 6주일 동안 치료를 하였다. 증례 1은 치유되었으나 1년 후에 재발하였고, 증례 2는 반응성이 미약하였기 때문에, 이 두 증례에 대하여 mitotane(op'-DDD, Lysodren)를 투여 하였던 바, 증례 1은 치유되고 증례 2에서는 피모(被毛)의 개선이 인정되었다. 포메라니안 종은 유전적으로 부신(副賢)에 있어서의 특정의 수산화효소가 결여(缺如)되어 있다는 것이 밝혀져 잠재적(潛在的)으로 고(高)프로게스테론, 고(高)안드로겐 증을 가지고 있다는 것이 보고 되어있다. 따라서 포메라니안 종에서는 고(高)코르티솔혈증을 나타내지 않고 부신피질의 과형성(過形成)을 일으키고 있는 것으로 생각된다. 부신피질을 선택적으로 파괴하는 작용을 가지는 Mitotane이 GH반응성탈모증에 유효하였기에 본 질환과 부신이 더욱 강하게 연관지어졌다. Two castrated male Pomeranians, having bilateral, symmetrical alopecia and hyperpigmentation, were diagnosed as growth hormone (GH) responsive dermatopathy by ACTH stimulation test, low dose dexamethasone suppression test and GH reactive test (xylazine response test). They were teated twice a week for six weeks by injecting 0.1 IU/㎏ of GH preparation into the muscle. Case 1 dog showed a significant recovery, but relapse occured after one year. Case 2 dog showed a low reactivity to it. Therefore both of them were treated with mitotane (op'-DDD, Lysodren®). Case 1 dog recovered and case 2 dog improved in coat. It is reported that Pomeranians hereditatily lacks in a specific hydroxylase activity and have potential hyperpogesteronemia and hyper-androgenemia. It is suggested that Pomeranians overproduce the adrenal cortex without showing hypercortisonemia. This result, that mitotane, as a seletive disintegrator of adrenal cortex, is efficacious against GH responsive dermatosis and give another support to the view that the disease is related with the function of adrenal cortex.